Erste Group Bank Has Weak Estimate for Amgen FY2026 Earnings

by · The Cerbat Gem

Amgen Inc. (NASDAQ:AMGN – Free Report) – Stock analysts at Erste Group Bank cut their FY2026 earnings estimates for Amgen in a research note issued to investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the medical research company will post earnings of $22.41 per share for the year, down from their prior forecast of $22.45. Erste Group Bank currently has a “Hold” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $22.31 per share.

A number of other analysts also recently issued reports on the company. Argus lowered their target price on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, May 20th. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings downgraded Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 15th. Truist Financial raised their price target on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research note on Tuesday, July 7th. Finally, UBS Group boosted their price target on Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $356.62.

Check Out Our Latest Research Report on Amgen

Amgen Trading Up 0.6%

Amgen stock opened at $366.24 on Monday. The firm has a 50-day moving average of $348.98 and a 200-day moving average of $351.05. Amgen has a one year low of $269.77 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company has a market cap of $197.66 billion, a price-to-earnings ratio of 25.49, a P/E/G ratio of 3.68 and a beta of 0.41.

Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter last year, the firm earned $4.90 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS.

Institutional Trading of Amgen

Several hedge funds and other institutional investors have recently modified their holdings of AMGN. Vanguard Group Inc. boosted its holdings in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares during the period. State Street Corp lifted its holdings in Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the last quarter. Capital World Investors lifted its holdings in Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the last quarter. Geode Capital Management LLC boosted its stake in Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. Finally, Norges Bank bought a new stake in Amgen in the 4th quarter valued at $2,164,162,000. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Amgen Company Profile

(Get Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Recommended Stories